Related Experiment Video
Updated: Jul 4, 2025

Investigating Target Gene Function in a CD40 Agonistic Antibody-induced Colitis Model using CRISPR/Cas9-based Technologies
Published on: June 2, 2021
Biomarkers That Predict Crohn's Disease Outcomes
Pablo A Olivera1,2, Mark S Silverberg1,2
1Zane Cohen Centre for Digestive Diseases, Lunenfeld Tanenbaum Research Institute, Mount Sinai Hospital, Toronto, Ontario, Canada.
Identifying biomarkers for Crohn's disease (CD) outcomes is crucial for personalized treatment. This review highlights promising markers like pharmacogenomic, transcriptomic, and microbiome signatures to guide therapy and predict complications.
Area of Science:
- Gastroenterology
- Immunology
- Genetics
Background:
- Crohn's disease (CD) is a chronic inflammatory digestive condition with complex prognosis and treatment challenges.
- Current prognostic factors have limitations, necessitating more precise biomarkers for early-stage and treatment-naive patients.
Purpose of the Study:
- To review and summarize current literature on promising biomarkers for predicting Crohn's disease outcomes.
- To discuss the potential clinical implications of these biomarkers in tailoring treatment and managing the disease.
Main Methods:
- Literature review of studies identifying biomarkers associated with CD prognosis, treatment response, and complications.
- Focus on pharmacogenomic, molecular, imaging, and microbiome-based markers.
Main Results:
- Pharmacogenomic markers (TPMT, NUDT15) predict thiopurine adverse events.
- HLA haplotypes, oncostatin M, and transcriptomic profiles correlate with anti-TNF therapy response.
- Confocal laser endomicroscopy, single-cell analyses, microbiome signatures, and proteomic profiles show potential for predicting treatment response and post-operative recurrence.
Conclusions:
- Biomarkers offer significant potential to personalize Crohn's disease management, improving treatment selection and outcome prediction.
- Further research and clinical validation are essential for integrating these biomarkers into routine patient care.
Related Concept Videos
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Inflammatory Bowel Disease II: Crohn's Disease
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by...
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Inflammatory Bowel Disease I: Ulcerative Colitis
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...

